What is the gold standard for ischemic stroke?

What is the gold standard for ischemic stroke?

An IV injection of recombinant tissue plasminogen activator (tPA) — also called alteplase (Activase) — is the gold standard treatment for ischemic stroke. An injection of tPA is usually given through a vein in the arm with the first three hours. Sometimes, tPA can be given up to 4.5 hours after stroke symptoms started.

What is stroke classification?

Strokes can be classified into two main types: ischaemic (i.e. caused by a clot in a blood vessel in the brain), or haemorrhagic (i.e. caused by a bleed in the brain) . These two main classifications allow further classification into subtypes (see Figure 1).

What is stroke prophylaxis?

Primary stroke prevention refers to the treatment of individuals with no history of stroke. Secondary stroke prevention refers to the treatment of individuals who have already had a stroke or transient ischemic attack.

When do you start anticoagulation after a stroke?

Guidelines from the American Heart Association/American Stroke Association state that it is reasonable to start anticoagulation 4 to 14 days after an acute ischemic stroke in the setting of A-fib.

Can ischemic stroke be cured?

To cure an ischemic stroke, doctors must dissolve the blood clot through either drugs or surgery. Common drugs used to cure ischemic stroke include tPA or aspirin, which help thin the blood and dissolve the clot in the brain. When drugs cannot be used, doctors may need to manually remove the clot through surgery.

When is heparin used for stroke?

Indications currently proposed by many experts for early full-dose IV heparin after stroke or transient ischemic attack (TIA) include the following:

  1. Conditions with potential high risk of early cardiogenic reembolization.
  2. Symptomatic dissection of the arteries supplying the brain.

What is anticoagulation after stroke?

Many experts recommend anticoagulation with IV heparin in the acute phase and subsequent oral anticoagulation for 3-24 months (target INR 2.5, range 2-3) followed by antiplatelet agents for at least 2 years. No large randomized trials have been performed to determine optimal treatment.

You Might Also Like